Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.

Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T; CAPNETZ Study Group..

Eur Respir J. 2008 Feb;31(2):349-55.

2.

[Biomarkers in community acquired pneumonia - what did we learn from the CAPNETZ study?].

Krüger S, Pletz MW, Rohde G.

Pneumologie. 2011 Feb;65(2):110-3. doi: 10.1055/s-0030-1255935. Review. German.

3.

The role of procalcitonin in community-acquired pneumonia: a literature review.

Lee M, Snyder A.

Adv Emerg Nurs J. 2012 Jul-Sep;34(3):259-71. doi: 10.1097/TME.0b013e318261338d. Review.

PMID:
22842969
4.

Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives.

Lippi G, Meschi T, Cervellin G.

Eur J Intern Med. 2011 Oct;22(5):460-5. doi: 10.1016/j.ejim.2011.02.023. Review.

PMID:
21925053
5.

Biomarkers and community-acquired pneumonia: tailoring management with biological data.

Torres A, Ramirez P, Montull B, Menéndez R.

Semin Respir Crit Care Med. 2012 Jun;33(3):266-71. doi: 10.1055/s-0032-1315638. Review.

PMID:
22718212
6.

Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.

Liu D, Su LX, Guan W, Xiao K, Xie LX.

Respirology. 2016 Feb;21(2):280-8. doi: 10.1111/resp.12704. Review.

7.

The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review.

Berg P, Lindhardt BØ.

Dan Med J. 2012 Mar;59(3):A4357. Review.

PMID:
22381083
8.

Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis.

Pfister R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, Machado MB, Piacentini E, Hammond NE, Ingram PR, Michels G.

Crit Care. 2014 Mar 10;18(2):R44. doi: 10.1186/cc13760. Review.

9.

Prediction of prognosis by markers in community-acquired pneumonia.

Viasus D, Simonetti A, Garcia-Vidal C, Carratalà J.

Expert Rev Anti Infect Ther. 2013 Sep;11(9):917-29. doi: 10.1586/14787210.2013.825442. Review.

PMID:
24053273
10.

Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis.

Yu CW, Juan LI, Wu MH, Shen CJ, Wu JY, Lee CC.

Br J Surg. 2013 Feb;100(3):322-9. doi: 10.1002/bjs.9008. Review.

PMID:
23203918
11.

Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin.

Niederman MS.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S127-32. doi: 10.1086/591393. Review.

PMID:
18986278
12.

Procalcitonin and community-acquired pneumonia (CAP) in children.

Giulia B, Luisa A, Concetta S, Bruna LS, Chiara B, Marcello C.

Clin Chim Acta. 2015 Dec 7;451(Pt B):215-8. doi: 10.1016/j.cca.2015.09.031. Review.

PMID:
26434548
13.

Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia?

Upadhyay S, Niederman MS.

Infect Dis Clin North Am. 2013 Mar;27(1):19-31. doi: 10.1016/j.idc.2012.11.003. Review.

PMID:
23398863
14.

Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI.

Leroy S, Fernandez-Lopez A, Nikfar R, Romanello C, Bouissou F, Gervaix A, Gurgoze MK, Bressan S, Smolkin V, Tuerlinckx D, Stefanidis CJ, Vaos G, Leblond P, Gungor F, Gendrel D, Chalumeau M.

Pediatrics. 2013 May;131(5):870-9. doi: 10.1542/peds.2012-2408. Review.

15.

Biomarkers in community-acquired pneumonia.

Krüger S, Welte T.

Expert Rev Respir Med. 2012 Apr;6(2):203-14. doi: 10.1586/ers.12.6. Review.

PMID:
22455492
16.

Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.

Schuetz P, Litke A, Albrich WC, Mueller B.

Curr Opin Infect Dis. 2013 Apr;26(2):159-67. doi: 10.1097/QCO.0b013e32835d0bec. Review.

PMID:
23434895
17.

Value of procalcitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta-analysis.

Huang SL, Lee HC, Yu CW, Chen HC, Wang CC, Wu JY, Lee CC.

Int J Tuberc Lung Dis. 2014 Apr;18(4):470-7. doi: 10.5588/ijtld.13.0449. Review.

PMID:
24670705
18.

Tools for outcome prediction in patients with community acquired pneumonia.

Khan F, Owens MB, Restrepo M, Povoa P, Martin-Loeches I.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):201-211. doi: 10.1080/17512433.2017.1268051. Review.

PMID:
27911103
19.

Diagnostic value of procalcitonin for bacterial infection in elderly patients - a systemic review and meta-analysis.

Lee SH, Chan RC, Wu JY, Chen HW, Chang SS, Lee CC.

Int J Clin Pract. 2013 Dec;67(12):1350-7. doi: 10.1111/ijcp.12278. Review.

PMID:
24246214
20.

[Diagnostic utility of procalcitonin in community-acquired respiratory tract infections--a literature review].

Wróblewski T, Marcisz C, Kurzawska G.

Postepy Hig Med Dosw (Online). 2004;58:495-505. Review. Polish.

Supplemental Content

Support Center